Literature DB >> 32533662

Pharmaceutical management of the COVID-19 pandemic in a mid-size hospital.

Laura Corregidor-Luna1, Francisco J Hidalgo-Correas1, Benito García-Díaz1.   

Abstract

The purpose of this article is to report the experience of the Department of Hospital Pharmacy of a mid-size hospital during the peak of the COVID-19 pandemic. The human and material resources available in a mid-size hospital were more limited than in larger hospitals of the region. In this article, we describe how this Department of Hospital Pharmacy was reorganized to meet the increase in activity, the strategies developed and the  lessons learned for future pandemics. The COVID-19 pandemic had a higher  impact in Leganes, a city in the south of Madrid, with a population of 190,000.  In the face of the dramatic increase in the proportion of patients attending our  hospital between March and April 2020, the Severo Ochoa University Hospital  increased the number of beds by 24.5% and fitted out new premises inside and  outside the hospital (sports centers). The mean number of patients seen in our  Emergency Department every day passed from 70-80 to a peak of 286 patients, with 652 hospitalized patients. The situation of emergency created by  this infectious disease, with management protocols changing constantly, had a  dramatic impact on the activity of hospital pharmacies. Thus, the pandemic has  affected areas of economic management, magistral preparation, dispensing of  medication to inpatients, ambulatory patients, patients monitored at home,  institutionalized patients, and patients from private hospitals and field hospitals.  Other areas affected include training, clinical trials, pharmacovigilance, and  counseling boards. Two strategies were adopted to overcome these problems: a  strategy centered on human resources (staff reinforcement, reallocation of  responsibilities), and a strategy centered on processes (some processes were  reinforced to meet the increase in activity, whereas other were temporarily suspended or reduced to the minimum).Conclusions: The Department of Hospital Pharmacy plays a key role  in hospitals and has been significantly reinforced to meet the dramatic impact of  the pandemic on this service. This Department has been able to reorganize its  processes and take over new responsibilities such as telepharmacy and home  dispensing. Hospital pharmacies play a crucial role in  pharmacotherapeutic decisions in hospitals. As in other Departments, training is  the area more significantly affected by the pandemic. Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32533662     DOI: 10.7399/fh.11499

Source DB:  PubMed          Journal:  Farm Hosp        ISSN: 1130-6343


  4 in total

1.  Redistribution of critical drugs in shortage during the first wave of COVID-19 in France: from operating theaters to intensive care units.

Authors:  Claire Chapuis; Rémy Collomp; Laura Albaladejo; Hugo Terrisse; Stéphane Honoré; Jean-Luc Bosson; Pierrick Bedouch; Pierre Albaladejo
Journal:  J Pharm Policy Pract       Date:  2022-04-01

2.  Impact of Remdesivir on the Treatment of COVID-19 During the First Wave in Spain.

Authors:  Alejandro Soriano; Rocío Montejano; José Sanz-Moreno; Juan Carlos Figueira; Santiago Grau; Robert Güerri-Fernández; Antonio Castro-Gómez; Inés Pérez-Román; Álvaro Hidalgo-Vega; Almudena González-Domínguez
Journal:  Adv Ther       Date:  2021-06-12       Impact factor: 3.845

3.  Social Restrictions versus Testing Campaigns in the COVID-19 Crisis: A Predictive Model Based on the Spanish Case.

Authors:  Francisco Javier Candel; Elisabet Viayna; Daniel Callejo; Raul Ramos; Jesús San-Roman-Montero; Pablo Barreiro; María Del Mar Carretero; Adam Kolipiński; Jesus Canora; Antonio Zapatero; Michael Chris Runken
Journal:  Viruses       Date:  2021-05-15       Impact factor: 5.048

4.  Drugs used during the COVID-19 first wave in Vitoria-Gasteiz (Spain) and their presence in the environment.

Authors:  S Domingo-Echaburu; M Irazola; A Prieto; B Rocano; A Lopez de Torre-Querejazu; A Quintana; G Orive; U Lertxundi
Journal:  Sci Total Environ       Date:  2022-01-19       Impact factor: 10.753

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.